Orion Biotechnology Canada

3:45 PM - 4:00 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Orion Biotechnology is a clinical stage Canadian Biotechnology company with operations in Switzerland and Poland. Orion’s primary research focus is the development of chemokine analogues for multiple indications.
Chemokine receptors play a critical role in various immunological responses & chemokine analogues are small proteins that have the potential to be safer than small molecule drugs and more potent than mAbs.
Orion has a proprietary chemokine analogue discovery platform that allows accelerated discovery & development of novel chemokine analogues across many therapeutic areas.
Our lead candidate is OB-002, a best-in-class CCR5 antagonist based on potency. It has an excellent safety profile.
Our lead indication is oncology where CCR5 is a validated target.
We have robust evidence showing that OB-002 has anticancer efficacy in animal models.
CCR5 is a novel target in MS and we have data that OB-002 is efficacious.
We start Phase 1 study of OB-002 for HIV prevention in Q3 2019
Company Type:
Company Website:
Company HQ State:
Ontario
Company HQ Country:
Canada
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
OB-002
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided